We could not find any results for:
Make sure your spelling is correct or try broadening your search.
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery techno... AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements. Show more
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.0481695568401 | 20.76 | 21.305 | 18.03 | 467476 | 19.53452605 | CS |
4 | -14.21 | -40.6464530892 | 34.96 | 35.25 | 18.03 | 658745 | 22.98666288 | CS |
12 | -16.11 | -43.7059142702 | 36.86 | 40.7 | 18.03 | 401153 | 28.4973094 | CS |
26 | -4.18 | -16.7669474529 | 24.93 | 41.3083 | 18.03 | 365994 | 29.16013469 | CS |
52 | 6.42 | 44.8011165387 | 14.33 | 41.3083 | 13.36 | 342262 | 26.00855627 | CS |
156 | -9.89 | -32.2780678851 | 30.64 | 41.3083 | 13.36 | 279420 | 24.51470076 | CS |
260 | 9.53 | 84.9376114082 | 11.22 | 41.3083 | 11.0506 | 312737 | 22.61764807 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions